Kalaris Total Assets from 2010 to 2025
| KLRS Stock | 8.87 0.54 6.48% |
Total Assets | First Reported 2019-12-31 | Previous Quarter 92.8 M | Current Value 81.2 M | Quarterly Volatility 113.5 M |
Check Kalaris Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalaris Therapeutics,'s main balance sheet or income statement drivers, such as Total Revenue of 0.0, Other Operating Expenses of 55.9 M or Research Development of 11.7 M, as well as many indicators such as Price To Sales Ratio of 71.68, Dividend Yield of 0.0 or PTB Ratio of 0.42. Kalaris financial statements analysis is a perfect complement when working with Kalaris Therapeutics, Valuation or Volatility modules.
Kalaris | Total Assets | Build AI portfolio with Kalaris Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalaris Stock Analysis
When running Kalaris Therapeutics,'s price analysis, check to measure Kalaris Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalaris Therapeutics, is operating at the current time. Most of Kalaris Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Kalaris Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalaris Therapeutics,'s price. Additionally, you may evaluate how the addition of Kalaris Therapeutics, to your portfolios can decrease your overall portfolio volatility.